Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and Response System
World Health Organization
juni 2025 · World Health Organization
E-bok
35
Sider
family_home
Kvalifisert
info
reportVurderinger og anmeldelser blir ikke kontrollert Finn ut mer
Om denne e-boken
In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions. Establishing a baseline understanding of RSV sequence diversity prior to the widespread rollout of immunization will help to inform the development of new diagnostic and therapeutic products, facilitate assessment of the effectiveness of immunization programmes, better understand viral diversity and evolution, and assess the potential impact of RSV variants on the effectiveness of interventions. This document outlines a number of practical considerations regarding the scale and quality of sequencing. It also outlines the range of next generation sequencing (NGS) technologies suitable for RSV whole genome sequencing (WGS).
Vurder denne e-boken
Fortell oss hva du mener.
Hvordan lese innhold
Smarttelefoner og nettbrett
Installer Google Play Bøker-appen for Android og iPad/iPhone. Den synkroniseres automatisk med kontoen din og lar deg lese både med og uten nett – uansett hvor du er.
Datamaskiner
Du kan lytte til lydbøker du har kjøpt på Google Play, i nettleseren på datamaskinen din.
Lesebrett og andre enheter
For å lese på lesebrett som Kobo eReader må du laste ned en fil og overføre den til enheten din. Følg den detaljerte veiledningen i brukerstøtten for å overføre filene til støttede lesebrett.
